6 days ago · 21 January 2025 New president says repeal is first of “many steps the US federal government will take to repair our institutions and our economy” | Defunct order aimed to lower drug costs and place caps on essential medications | Big Pharma argues higher drug prices are necessary to fund R&D for new therapies.

Jan 28, 2025 · Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent wants another trial.

10 hours ago · 29 August 2024 Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.

10 hours ago · LSIPR sister title releases USA Patents Rankings, divided into categories of non-contentious and contentious work | Listing identifies the go-to firms and individuals for prosecution, litigation and strategic work in the US.

14 November 2024 Transatlantic deal would make ‘HSF Kramer’ a top 20 global firm by revenue | ‘Transformational’ combination a ‘one-of-a-kind’ opportunity, say firms’ leaders | HSF Kramer would have 2,700 lawyers, including 640 partners across 25 offices | IP practice would have approximately 32 partners.

19 December 2024 News Americas Danielle Burns Principal Philips Ormonde Fitzpatrick, David Longmuir Principal Philips Ormonde Fitzpatrick, Jason Murata Partner Axinn Veltrop & Harkrider, Michael Davitz Partner Leason Ellis

3 December 2024 German biotech asks federal judge to reject Amgen’s efforts to narrow scope of a key patent in ongoing dispute | Patent relates to Lindis' cancer immunotherapy treatment | Lindis calls on court to uphold the broader interpretation and claims Amgen’s attempt to narrow is inconsistent with the patent's history.

LSIPR Autumn 2021. This issue examines big pharma's five-step plan, its alternative to the controversial IP waiver. Elsewhere, it analyses the impact of China's latest IP laws, the potentially chilling effect of the ‘essentially derived varieties’ concept protecting plant varieties, and experimental use exemptions in the UK, plus more.

Jan 27, 2025 · LSPN Fall 2024 took place on October 15-16 in San Francisco, gathering an unrivalled assembly of in-house patent counsel, intellectual property professionals, and industry leaders from pharmaceutical and biotechnology companies. The event offered a unique opportunity to explore developments in the ...

About. Life Sciences Intellectual Property Review tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.From gene patents to stem cell research, we hope to provide the best news and analysis. For information about Single Licence and Corporate Licence subscription options, please contact Adrian Tapping: [email protected] ...